Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
TCF12
REST API REST API
Homo sapiens
TCF12 is differentially expressed in 322 experiments: 112 organism parts: bone marrow, thymus, ... (110 more);, 165 disease states: normal, control, ... (163 more);, 94 cell types 433 cell lines 49 compound treatments and 75 other conditions.
Synonyms HsT17266, HTF4, HEB, bHLHb20
Orthologs tcf12 (Danio rerio)   Tcf12 (Rattus norvegicus)   Tcf12 (Mus musculus)   TCF12 (Gallus gallus)   TCF12 (Bos taurus)   tcf12 (Xenopus laevis)   TCF12 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, protein binding, regulation of transcription, DNA-dependent, transcription, DNA-dependent, positive regulation of gene expression, cell differentiation, multicellular organismal development, nucleus, muscle organ development, protein heterodimerization activity, transcription factor complex, immune response, nervous system development, regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, positive regulation of neuron differentiation, E-box binding, sequence-specific DNA binding transcription factor activity, transcription regulatory region DNA binding
InterPro Term HLH_DNA-bd
UniProt Accession Q99081, Q9NQY4, Q9NQY5, Q9NQY6, Q9NQY7, Q9NQY9, Q9NQY1, Q9NQY2, Q9NQY3, B4DZP2, B4E1W1, B4DGI9, F5GY10, E9PGY0, F5H6Z6, F5H5E9
Search EB-eye ENSG00000140262
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-6573, E-MEXP-433, E-GEOD-3526, E-MTAB-62, ... (27 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (42 experiments)

Factor Value U/D Experiments
Jurkat
3
E-GEOD-1880, E-MEXP-2197, E-MTAB-62
HL-60
1
3
E-MTAB-37, E-GEOD-24147, E-GEOD-5258, E-GEOD-96
BT474
2
E-MEXP-440, E-MTAB-37
HCC1937
2
E-MTAB-37, E-MTAB-62
HCC2157
2
E-MTAB-37, E-MTAB-62
MCF-7
2
E-GEOD-20081, E-GEOD-19639
427 more value(s).


Cell type

studied in E-GEOD-22529, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, ... (48 experiments)

Factor Value U/D Experiments
human embryonic stem cell
2
E-GEOD-18265, E-GEOD-18147
fibroblast
2
E-GEOD-3920, E-GEOD-3204
stromal cell
1
2
E-MEXP-2034, E-GEOD-3998, E-GEOD-1460
CD4+ T cell
1
2
E-GEOD-16190, E-AFMX-5, E-MTAB-24
CXCR4 negative
1
E-GEOD-15893
secretory cell
1
E-GEOD-3998
88 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-16363, E-MTAB-62, E-GEOD-5418, ... (67 experiments)

Factor Value U/D Experiments
colon carcinoma
3
E-MTAB-37, E-MTAB-57, E-GEOD-3726
sarcoma
2
E-GEOD-2719, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
neuroblastoma
2
E-MTAB-37, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
acute promyelocytic leukemia
1
2
E-GEOD-995, E-MTAB-62, E-GEOD-1729
159 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-1417, E-GEOD-5741, E-GEOD-697, ... (31 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-GEOD-3720, E-MEXP-1958
control
1
2
E-GEOD-3284, E-GEOD-995, E-GEOD-4006
4,5-dianilinophthalimide
1
1
E-GEOD-5258
ox-LDL
1
E-GEOD-5741
gamma-secretase inhibitor DAPT
1
E-GEOD-6495
N-nitrosodimethylamine
1
E-GEOD-6907
43 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-1563, E-GEOD-21589, E-GEOD-16363, ... (13 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-1743, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-TABM-145, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-22541, E-GEOD-2509, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720, E-GEOD-4086

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-4025, E-MEXP-1482, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (8 experiments)

Genotype
studied in E-GEOD-1923, E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-TABM-321, ... (11 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-13073, E-MEXP-1220, E-GEOD-5681, E-MEXP-2657, E-TABM-127, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-MTAB-197, E-GEOD-2466, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, ... (7 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-19703, E-GEOD-1493, E-GEOD-22309, E-GEOD-1460, E-GEOD-17636, ... (7 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-10896

RNAi
studied in E-GEOD-1676, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-4922, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-1561, E-GEOD-4922

weight of protein recovered
studied in E-GEOD-21918

Processing time: 0.369 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM